CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Bookmark and Share
Published: 7 Oct 2019
Views: 1136
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands

Prof Ronald de Wit speaks to ecancer at ESMO 2019 in Barcelona about the CARD study.

He outlines the background and study design, and the premise for this particular design.

Prof de Wit explains the positive results, and also the robust nature of the data. He believes that cabazitaxel will be practise changing, and is well tolerated.